ArticleFrontiers in immunology2025

Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis.

Jiao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.